Search Results
Jan 28, 2026, 09:00 ET MRI Software Appoints Nihar Malik as Chief Innovation Officer
operational excellence, and M&A execution to advance the company's market positioning and growth initiatives. Malik also held senior leadership roles at XPO Logistics, Inc. and The Hertz Corporation. Earlier in his career, Malik was an Associate Principal with McKinsey & Company, advising global businesses
More news about: MRI Software
Jan 26, 2026, 16:00 ET WWEX Group Celebrates Carrier Excellence With 2026 Carrier Awards
Conference on Jan. 20 in San Diego, are:West Coast LTL Carrier of the Year – EstesNational LTL Carrier of the Year – XPOLTL Carrier Partner of the Year – R&L CarriersSoutheast LTL Carrier of the Year – ACT LogisticsMidwest LTL Carrier of the
More news about: WWEX Group
Jan 12, 2026, 07:00 ET Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed
More news about: Karyopharm Therapeutics Inc.
Jan 02, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received
More news about: Karyopharm Therapeutics Inc.
Dec 16, 2025, 20:00 ET Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
seeking effective therapies.With a novel mechanism of action, XPOVIO® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of
More news about: Antengene Corporation Limited
Dec 10, 2025, 14:16 ET Menarini Group apresenta os dados da fase 2 da combinação de elacestranto (ORSERDU®) em pacientes com câncer de mama metastático (mBC) ER+, HER2- no San Antonio Breast Cancer Symposium 2025 (SABCS)
câncer hematológico agressivo, nos Estados Unidos, Europa e outras regiões globais. Além disso, a Stemline comercializa o selinexor, um inibidor de XPO1 para mieloma múltiplo, na Europa. A empresa também está conduzindo vários estudos de expansão de rótulo com elacestranto e tagraxofusp em indicações
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 14:02 ET Menarini Group presenta datos de combinación de fase 2 de Elacestrant (ORSERDU®) en pacientes con cáncer de mama metastásico (CMM) ER+, con HER2 en el Simposio de Cáncer de Mama 2025 en San Antonio
cáncer hematológico agresivo, en Estados Unidos, Europa y otras regiones del mundo. Por otra parte, Stemline comercializa selinexor, un inhibidor de XPO1 para el mieloma múltiple, en Europa. Adicionalmente, la empresa también lleva a cabo múltiples estudios de expansión de etiquetas con elacestrant y
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 23:19 ET Il Gruppo Menarini presenta i dati di fase 2 sulla combinazione di elacestrant (ORSERDU®) in pazienti affetti da carcinoma mammario metastatico (mBC) ER+, HER2- al Simposio sul cancro al seno di San Antonio del 2025
ematologico aggressivo, negli Stati Uniti, in Europa e in altre regioni del mondo. Inoltre, in Europa Stemline commercializza selinexor, un inibitore di XPO1 per il mieloma multiplo. L'azienda è impegnata anche in diversi studi di espansione delle etichette con elacestrant e tagraxofusp, rispettivamente nelle
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 14:24 ET Menarini Group 於 2025 年聖安東尼奧乳癌研討會公佈 Elacestrant (ORSERDU®) 針對 ER+、HER2- 轉移性乳癌 (mBC) 患者的第 2 期聯合治療數據
突變晚期或轉移性乳癌的已停經女性或成年男性，並接受最少一種內分泌療法後，病情出現惡化。Stemline 也於美國、歐洲和全球其他地區，商業化針對 CD123 的新型標靶藥物 tagraxofusp-erzs。這藥物用於治療母細胞性漿細胞樣樹突狀細胞腫瘤 (BPDCN)，即侵襲性血液癌症。此外，Stemline 於歐洲商業化 selinexor，這是治療多發性骨髓瘤的 XPO1抑制劑。該公司還就乳癌和血液系統癌症適應症，分別利用 elacestrant 和 tagraxofusp 作多項標籤擴展研究，並為實體癌症和血液系統癌症病人的其他候選藥物，擁有處於不同研發階段的廣泛臨床管線。[1] Lloyd et al. Clinical and genomic factors associated
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 11:38 ET El Grupo Menarini presenta datos de la combinación de fase 2 de Elacestrant (ORSERDU®) en cáncer de mama
cáncer hematológico agresivo, en Estados Unidos, Europa y otras regiones del mundo. Además, Stemline comercializa en Europa selinexor, un inhibidor de XPO1 para el mieloma múltiple. La compañía también está realizando múltiples estudios de expansión de marca con elacestrant y tagraxofusp en indicaciones
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 15:17 ET Le groupe Menarini présente les données de la phase 2 sur l'association d'Elacestrant (ORSERDU®) chez des patientes atteintes d'un cancer du sein métastatique (mBC) ER+, HER2- lors du 2025 San Antonio Breast Cancer Symposium
cellules dendritiques plasmacytoïdes (BPDCN), un cancer hématologique agressif. En outre, Stemline commercialise en Europe le selinexor, un inhibiteur de XPO1 pour le traitement du myélome multiple. La société mène également de multiples études d'extension d'étiquette avec l'élacestrant et le tagraxofusp dans
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 14:47 ET Menarini Group präsentiert Daten zur Phase-2-Kombination von Elacestrant (ORSERDU®) bei Patientinnen mit ER+, HER2- metastasiertem Brustkrebs (mBC) auf dem San Antonio Breast Cancer Symposium 2025
hämatologischen Krebserkrankung, in den Vereinigten Staaten, Europa und anderen globalen Regionen. Darüber hinaus vertreibt Stemline in Europa Selinexor, einen XPO1-Inhibitor zur Behandlung des multiplen Myeloms. Das Unternehmen führt außerdem mehrere Studien zur Erweiterung der Indikation mit Elacestrant und Tagraxofusp
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:41 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
(BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:30 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
(BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 07:00 ET Karyopharm to Participate in Baird's Biotech Discovery Series
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory
More news about: Karyopharm Therapeutics Inc.
Dec 04, 2025, 02:20 ET Retail and Warehouse Logistics Market to Reach $2.3 Trillion, Globally, by 2034 at 5.9% CAGR: Allied Market Research
https://www.alliedmarketresearch.com/retail-and-warehouse-logistics-market/purchase-optionsLeading Market Players: -DHL GroupXPO LogisticsKuehne + NagelDB SchenkerFedExUPS Supply Chain SolutionsC.H. Robinson Worldwide, Inc.GeodisCEVA
More news about: Allied Market Research
Dec 01, 2025, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received
More news about: Karyopharm Therapeutics Inc.
Dec 01, 2025, 07:00 ET Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory
More news about: Karyopharm Therapeutics Inc.
Nov 26, 2025, 05:28 ET Il Gruppo Menarini annuncia che, al 67° Congresso Annuale dell'American Society of Hematology, presenterà nuovi dati su ELZONRIS® (tagraxofusp-erzs)
ematologico aggressivo, negli Stati Uniti, in Europa e in altre regioni del mondo. Inoltre, in Europa Stemline commercializza selinexor, un inibitore di XPO1 per il mieloma multiplo. L'azienda è impegnata anche in diversi studi di espansione delle etichette con elacestrant e tagraxofusp, rispettivamente nelle
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 25, 2025, 08:36 ET Menarini Group 宣佈將於第 67 屆美國血液學會年會暨展覽會 (67th American Society of Hematology Annual Meeting and Exposition) 發表 ELZONRIS® (tagraxofusp-erzs) 最新數據
突變晚期或轉移性乳癌的已停經女性或成年男性，並接受最少一種內分泌療法後，病情出現惡化。Stemline 也於美國、歐洲和全球其他地區，商業化針對 CD123 的新型標靶藥物 tagraxofusp-erzs。這藥物用於治療母細胞性漿細胞樣樹突狀細胞腫瘤 (BPDCN)，即侵襲性血液癌症。此外，Stemline 於歐洲商業化 selinexor，這是治療多發性骨髓瘤的 XPO1抑制劑。該公司還就乳癌和血液系統癌症適應症，分別利用 elacestrant 和 tagraxofusp 作多項標籤擴展研究，並為實體癌症和血液系統癌症病人的其他候選藥物，擁有處於不同研發階段的廣泛臨床管線。
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 25, 2025, 05:07 ET Menarini Group anuncia nuevos datos sobre ELZONRIS ® (tagraxofusp-erzs) que se presentarán en la 67ª Reunión y Exposición Anual de la Sociedad Americana de Hematología
(BPDCN), un cáncer hematológico agresivo, en Estados Unidos, Europa y otras regiones del mundo. Además, Stemline comercializa selinexor, un inhibidor de XPO1 para el mieloma múltiple, en Europa. La empresa también está llevando a cabo múltiples estudios de expansión de etiquetas con elacestrant y tagraxofusp
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 25, 2025, 05:04 ET Menarini Group anuncia novos dados sobre ELZONRIS® (tagraxofusp-erzs) a serem apresentados na 67ª Reunião e Exposição Anual da Sociedade Americana de Hematologia
câncer hematológico agressivo, nos Estados Unidos, Europa e outras regiões globais. Além disso, a Stemline comercializa o selinexor, um inibidor de XPO1 para mieloma múltiplo, na Europa. A empresa também está conduzindo vários estudos de expansão de rótulo com elacestranto e tagraxofusp em indicações
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 25, 2025, 04:53 ET Menarini Group anuncia nuevos datos sobre ELZONRIS® (tagraxofusp-erzs)
cáncer hematológico agresivo, en Estados Unidos, Europa y otras regiones del mundo. Además, Stemline comercializa en Europa selinexor, un inhibidor de XPO1 para el mieloma múltiple. La compañía también está realizando múltiples estudios de expansión de marca con elacestrant y tagraxofusp en indicaciones
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 16:52 ET Menarini Group gibt neue Daten zu ELZONRIS® (Tagraxofusp-erzs) bekannt, die auf der 67. Jahrestagung und Ausstellung der American Society of Hematology vorgestellt werden
hämatologischen Krebserkrankung, in den Vereinigten Staaten, Europa und anderen globalen Regionen. Darüber hinaus vertreibt Stemline in Europa Selinexor, einen XPO1-Inhibitor zur Behandlung des multiplen Myeloms. Das Unternehmen führt außerdem mehrere Studien zur Erweiterung der Indikation mit Elacestrant und Tagraxofusp
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 16:44 ET Menarini Group annonce de nouvelles données sur ELZONRIS® (tagraxofusp-erzs) qui seront présentées lors de la 67e réunion annuelle de l'American Society of Hematology
cellules dendritiques plasmacytoïdes (BPDCN), un cancer hématologique agressif. En outre, Stemline commercialise en Europe le selinexor, un inhibiteur de XPO1 pour le traitement du myélome multiple. La société mène également de multiples études d'extension d'étiquette avec l'élacestrant et le tagraxofusp dans
More news about: Menarini Industrie Farmaceutiche Riunite